Erythropoiesis-Stimulating Agents (ESAs)
Endocrine Pharmacology and Anti-Doping Considerations
Erythropoiesis-Stimulating Agents (ESAs)
Erythropoiesis-stimulating agents activate erythropoietin-related pathways to increase red-cell production in selected medical conditions.
Therapeutic effects and feedback
Endocrine medicines can replace deficient signals, activate or block receptors, or change hormone synthesis and metabolism. Physiological replacement differs from supraphysiological exposure. Dose, route, duration, comorbidities and feedback suppression influence both benefit and harm.
Specific considerations
Excessive or inappropriate exposure can increase thrombotic and cardiovascular risk, and a higher hemoglobin concentration is not an unrestricted physiological benefit.
Clinical and sporting context
Legitimate treatment and anti-doping eligibility are separate questions. The current prohibited list, route-specific rules and applicable TUE process must be checked through official sources. Mechanistic descriptions should not be used to design unsupervised performance-enhancing drug protocols.
Home
Academy
Site Map